AzTrials
AzTrials

Excessive Daytime SleepinessDS-MWT2NCT06872593

Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal

A study testing CPAP-withdrawal and Test Sequence in people with Excessive Daytime Sleepiness and Obstructive Sleep Apnea (OSA), run by Stefan Lakämper at 1 site in Switzerland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In brief, the proposed study will evaluate a recently proposed naturalistic, driving simulation test to identify and measure sleepiness behind the wheel, one of the most underestimated causes of road accidents. Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
CPAP-withdrawal and Test Sequence
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
54 participants
Where
1 siteSwitzerland
Study dates
14 Jul 2025to 30 Apr 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Inclusion Criteria (OSA patients): adult drivers, diagnosed OSA, established CPAP-treatment regime, highly adherent and compliant within the last 6 months (>5h, >80% of days), at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)

Inclusion criteria (healthy comparison croup): adult drivers, no declared psychiatric disorders, no declared sleep-related diagnosis, at impaired eyesight with more than +/- 5 diopter or astigmatism, contact lenses are required (for eye tracking)

Exclusion criteria (for both groups): sensibility to motion sickness (kinetosis, dizziness, etc. in 5 min screening drive), professional drivers (if working during the study period), inability to understand the study procedure for linguistic or cognitive reasons.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Stefan Lakämper, Dr. rer. nat. contact

+41793789984

stefan.lakaemper@irm.uzh.ch

Veronika Gambin, MSc contact

+41797149386

veronika.gambin@irm.uzh.ch

Switzerland1 site, 1 recruiting
  • Division of Traffic Medicine, Institute of Forensic Medicine, University of Zurich

    Zurich, ZRH, 8050

    Stefan Lakämper, Dr. rer. nat., +41793789984, stefan.lakaemper@irm.uzh.ch

    Veronika Gambin, +41797149386, nan.li@irm.uzh.ch

    Recruiting

Other trials in Switzerland

About this study

Official title: Validating a Novel Driving Simulation-based MWT Against the Standard MWT in an OSA-cohort Challenged by CPAP-withdrawal - a Monocentric, Controlled, Randomized, Crossover Trial

In brief, the proposed study will evaluate a recently proposed naturalistic, driving simulation test to identify and measure sleepiness behind the wheel, one of the most underestimated causes of road accidents. The proposed test offers higher ecological validity and might complement somnological tests that are standard, but rarely performed. Thus, the test might provide traffic medicine and sonologists with an effective tool, that can also directly convey the risks of excessive daytime sleepiness to drivers and thus, in combination, effectively aid in traffic medicine's mandate to avoid preventable road fatalities.

Excessive daytime sleepiness (EDS) is a symptomatic condition resulting from too little or compromised sleep, caused by psycho-social stress (shiftwork, lifestyle) or medical conditions (obstructive sleep apnoea (OSA), narcolepsy). Driving with untreated EDS might lead to sleepy/drowsy driving and microsleep, which is considered to be one of the highest-ranking causes of road accidents. Sleepiness and its dangers on the wheel might subjectively not be registered by the affected drivers. Also, subjective sleepiness might not correlate with somnological measurements that are also crucial for legally determining the fitness to drive (FTD).

Read more

There exists a variety of partially complementary tools to evaluate the extent of EDS. Mean sleep latency obtained in the maintenance of wakefulness test (MWT) is widely, but not uniformly, considered to be one of the most objective measures to evaluate EDS, especially in the context of driving performance. However, there is inconsistent or insufficient evidence for MWTs to reliably predict the FTD in general, potentially as its result might be strongly influenced by motivation. Moreover, patients might not relate low mean MWT-latencies to their own and other's risks in traffic.

A need for improved tools to measure EDS was formulated. It remains open, whether the MWT should be replaced or complemented by, for example, future road-side metabolomics-tests detecting sleepiness in traffic or whether the MWT should be adapted to better convey a.) the risks of EDS in traffic and b.) its meaning for the determination of the FTD.

With this need in mind the investigators proposed furnishing the maintenance of wakefulness test with improved ecological validity to provide an improved tool for the assessment of the effect of excessive daytime sleepiness on the fitness to drive: recently published results from an exploratory feasibility study suggested it to be well possible to transfer the MWT-paradigm to a driving simulator (DS) with high user acceptance. The published result's implication and relevance was well received: the new test, DS-MWT, might complement somnological MWTs in pneumology and neurology. I might provide a naturalistic and relatable tool to determine EDS in traffic medicine, who is institutionally responsible for determining the FTD. This is also desirable, because prohibitively high cost - in time, money and instrumentation - often prevent a standard MWT in standard care of sleep-related medical conditions. Potentially, the use of the DS-MWT might help reduce the number of preventable road fatalities by more often identifying sleepy individuals before they get behind the wheel.

However, for this goal to be achieve, it remains to be evaluated whether the latencies obtained in classical or simulation conditions are comparable and whether obtained latencies actually reflect other clinical parameters of EDS relating to underlying medical conditions, such as for example OSA. This represents a significant gap of evidence for both medical experts in pneumology and traffic medicine, but also for affected drivers. This gap will be filled by systematically comparing classical and simulation-based MWTs by means of their resulting latencies. In a within-study setup of 36 highly adherent OSA-patients, experiments will be related to a main medical comparator, a ≥7-day continuous positive airway pressure (CPAP)-withdrawal (W) and subsequent -resumption or continuation (C), respectively. There will be a control group of 18 healthy participants for comparison.

Being tested
CPAP-withdrawal, Test Sequence
Keywords
sleep, drowsy driving, sleepy driving, sleepiness behind the wheel, driving simulation, CPAP treatment, CPAP withdrawal, driving performance, sleep latency, maintenance of wakefulness test, MWT, microsleep, microsleep-like episodes, eye tracking, EEG-recording
Medical subject headings
Disorders of Excessive Somnolence, Sleep Apnea, Obstructive

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CPAP-withdrawalProcedure or surgery

    7-day-long CPAP-withdrawal

  • Test SequenceDiagnostic test

    Test Sequence M or D as specified in arm description

Study groups in NCT06872593
Study groupRoleWhat they receive
OSA - W(first) + MDExperimentalallocated OSA-participants will perform test sequence M -> D first after 7d CPAP-withdrawal, then after ≥7d CPAP.
Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence
OSA - W(first) + DMExperimentalallocated OSA-participants will perform test sequence D -> M first after 7d CPAP-withdrawal, then after ≥7d CPAP.
Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence
OSA - C(first) + MDExperimentalallocated OSA-participants will perform test sequence M -> D first after ≥7d CPAP, then after 7d CPAP-withdrawal.
Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence
OSA - C(first) + DMExperimentalallocated OSA-participants will perform test sequence D-> M first after ≥7d CPAP, then after 7d CPAP-withdrawal.
Receives: Procedure: CPAP-withdrawal; Diagnostic Test: Test Sequence
Healthy control MD - DMOtherhealthy participants will perform test sequence M -> D first , then D -> M
Receives: Diagnostic Test: Test Sequence
Healthy control DM - MDOtherhealthy participants will perform test sequence D -> M first , then M -> D.
Receives: Diagnostic Test: Test Sequence

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. significant difference between mean MWT- and DS-MWT-latencies

    significant difference between mean latencies measured in classical maintenance of wakefulness test (MWT, M) and driving simulation-based maintenance of wakefulness test (DS-MWT, D) and DS-MWT-latencies.

    Measured: MWT- and DS-MWT-latencies are measured in two consecutive days during CPAP-treatment and after 7 days CPAP-withdrawal (intervention) in randomized order.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Mar 2025
  2. Study start14 Jul 2025
  3. Primary completion30 Apr 2027 (estimated)
  4. Study completion30 Apr 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Crossover
Model description
monocentric, controlled, randomized, crossover trial, with two groups and four arms, plus a two-armed crossover control group
Masking
None (open label)
Enrolment
54 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06872593
Sponsor's protocol ID
DS-MWT2
Acronym
DS-MWT2
Status last verified
Mar 2025
First submitted
6 Mar 2025
Last updated
17 Jul 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: Results will be published in peer-reviewed journals. Anonymized raw data will be made available upon request.

Publications

  • Pisteljic M, Keller K, Lakamper S. Capturing sleep accidents in driving simulation as a promising tool to assess excessive daytime sleepiness with high ecological validity-a pilot study. Sleep. 2024 Aug 14;47(8):zsae110. doi: 10.1093/sleep/zsae110. No abstract available.

    PubMed 38758109
  • Gambin V, Li N, Schwarz EI, Keller K, Lakamper S. Validating a novel driving simulation-based MWT against the standard MWT in an OSA-cohort challenged by CPAP-withdrawal (DS-MWT2) - Protocol for a monocentric, controlled, randomized, crossover trial. PLoS One. 2026 Jul 9;21(7):e0341997. doi: 10.1371/journal.pone.0341997. eCollection 2026.

    PubMed 42424269

Questions about this trial

What is this clinical trial studying?

A study testing CPAP-withdrawal and Test Sequence in people with Excessive Daytime Sleepiness and Obstructive Sleep Apnea (OSA), run by Stefan Lakämper at 1 site in Switzerland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 17 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Switzerland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Stefan Lakämper, Dr. rer. nat. (+41793789984, stefan.lakaemper@irm.uzh.ch), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

significant difference between mean MWT- and DS-MWT-latencies (time frame: MWT- and DS-MWT-latencies are measured in two consecutive days during CPAP-treatment and after 7 days CPAP-withdrawal (intervention) in randomized order.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06872593, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jul 2025.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in